Literature DB >> 27123874

Acute and subacute idiopathic interstitial pneumonias.

Hiroyuki Taniguchi1, Yasuhiro Kondoh1.   

Abstract

Idiopathic interstitial pneumonias (IIPs) may have an acute or subacute presentation, or acute exacerbation may occur in a previously subclinical or unrecognized chronic IIP. Acute or subacute IIPs include acute interstitial pneumonia (AIP), cryptogenic organizing pneumonia (COP), nonspecific interstitial pneumonia (NSIP), acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and AE-NSIP. Interstitial lung diseases (ILDs) including connective tissue disease (CTD) associated ILD, hypersensitivity pneumonitis, acute eosinophilic pneumonia, drug-induced lung disease and diffuse alveolar haemorrhage need to be differentiated from acute and subacute IIPs. Despite the severe lack of randomized controlled trials for the treatment of acute and subacute IIPs, the mainstream treatment remains corticosteroid therapy. Other potential therapies reported in the literature include corticosteroids and immunosuppression, antibiotics, anticoagulants, neutrophil elastase inhibitor, autoantibody-targeted treatment, antifibrotics and hemoperfusion therapy. With regard to mechanical ventilation, patients in recent studies with acute and subacute IIPs have shown better survival than those in previous studies. Therefore, a careful value-laden decision about the indications for endotracheal intubation should be made for each patient. Noninvasive ventilation may be beneficial to reduce ventilator associated pneumonia.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  acute exacerbation of idiopathic pulmonary fibrosis; acute interstitial pneumonia; cryptogenic organizing pneumonia; non-specific interstitial pneumonia

Mesh:

Substances:

Year:  2016        PMID: 27123874     DOI: 10.1111/resp.12786

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

1.  Seven patients with cryptogenic organizing pneumonia succesfully treated with clarithromycin.

Authors:  Fatma Ciftci; Özlem Özdemir Kumbasar
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  Interstitial inflammation and pulmonary fibrosis in COVID-19: The potential role of cytostatic therapy for severe lung injury.

Authors:  Elena V Filimonova; Lyubov A Davydova; Mariana A Lysenko; Sergey V Tsarenko
Journal:  Respir Med Case Rep       Date:  2022-05-27

Review 3.  Acute fibrinous and organizing pneumonia as initial presentation of primary Sjögren's syndrome: a case report and literature review.

Authors:  Yukai Wang; Shucan Zhao; Guangzhou Du; Songkun Ma; Qisheng Lin; Jianqun Lin; Kedi Zheng; Guohong Zhang; Marco Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2018-05-02       Impact factor: 2.980

4.  Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia.

Authors:  Kota Murohashi; Yu Hara; Yusuke Saigusa; Nobuaki Kobayashi; Takashi Sato; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

Review 5.  Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research.

Authors:  Lieuwe D J Bos; Antonio Artigas; Jean-Michel Constantin; Laura A Hagens; Nanon Heijnen; John G Laffey; Nuala Meyer; Laurent Papazian; Lara Pisani; Marcus J Schultz; Manu Shankar-Hari; Marry R Smit; Charlotte Summers; Lorraine B Ware; Raffaele Scala; Carolyn S Calfee
Journal:  Eur Respir Rev       Date:  2021-02-02

6.  An Infant with Interstitial Lung Disease.

Authors:  Pankaj C Vaidya; Pandiarajan Vignesh; Kushaljit Singh Sodhi; Meenu Singh; Uma Nahar
Journal:  Indian Pediatr       Date:  2019-02-15       Impact factor: 1.411

7.  Hashimoto's thyroiditis-induced cryptogenic organizing pneumonia: A case report.

Authors:  Litao Guo; Bo Chen; Lei Zhang; Yuan Deng; Hao Li; Qin Dong Shi
Journal:  Exp Ther Med       Date:  2019-10-30       Impact factor: 2.447

Review 8.  What is pneumonia?

Authors:  Grant Waterer
Journal:  Breathe (Sheff)       Date:  2021-09

Review 9.  Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights.

Authors:  Paola Faverio; Federica De Giacomi; Luca Sardella; Giuseppe Fiorentino; Mauro Carone; Francesco Salerno; Jousel Ora; Paola Rogliani; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Grazia Messinesi; Alberto Pesci; Antonio Esquinas
Journal:  BMC Pulm Med       Date:  2018-05-15       Impact factor: 3.317

10.  Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease.

Authors:  Takafumi Koyauchi; Hideki Yasui; Noriyuki Enomoto; Hirotsugu Hasegawa; Hironao Hozumi; Yuzo Suzuki; Masato Karayama; Kazuki Furuhashi; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Koshi Yokomura; Takafumi Suda
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.